Regenxbio
RGNX
159 hedge funds and large institutions have $345M invested in Regenxbio in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 50 reducing their positions, and 28 closing their positions.
21% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $972K
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
16% more capital invested
Capital invested by funds: $298M → $345M (+$47M)
0.19% more ownership
Funds ownership: 83.18% → 83.37% (+0.19%)
3% less funds holding
Funds holding: 164 → 159 (-5)
11% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 28
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.9M |
| 2 |
Goldman Sachs
New York
|
+$8.64M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.51M |
| 4 |
Renaissance Technologies
New York
|
+$3.67M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.97M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.16M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.03M |
| 4 |
JP Morgan Chase
New York
|
-$4.29M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.56M |
RGNX Hedge Fund Activity: Q2 2025 in Review
159 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2025, worth a combined $345M — up 16% from $298M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of RGNX and 25 opened new positions — a net loss of 3 holders — while 50 trimmed existing stakes and 60 added.
The largest buyer was BlackRock, adding an estimated $10.9M. The largest seller was Morgan Stanley, cutting an estimated $8.97M.
- 159 institutional investors held Regenxbio (RGNX) as of Q2 2025, down from 164 in Q1 2025.
- Funds reported $345M of Regenxbio stock for Q2 2025, up 16% quarter-over-quarter.
- 25 funds opened new Regenxbio positions in Q2 2025 and 28 closed out, a net change of -3 holders.
- The largest Regenxbio buyer in Q2 2025 was BlackRock, an estimated $10.9M added.
- The largest Regenxbio seller in Q2 2025 was Morgan Stanley, an estimated $8.97M sold.
Based on aggregated 13F filings for Q2 2025.